drugset / Trial / NCT06939036
Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )
NaSingle-groupOpen-labelTreatment
Summary
This study aims to determine safety, tolerability, recommended phase 2 dose (RP2D), and preliminary antitumor activity of 225Ac-SSO110 with standard of care (SoC) therapy in patients with somatostatin receptor 2 expressing (SSTR2+) extensive-stage small cell lung cancer (ES-SCLC) and recurrent locally advanced or metastatic Merkel cell carcinoma (MCC).
Timeline
- Start
- 2025-07-01
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
Outcome
Outcome not reported
Stopped (Business): “Study terminated due to strategic business decisions.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 225Ac-SSO110 | Unknown | — | — |
| Background | Atezolizumab | Monoclonal antibody | — | — |
| Background | Avelumab | Monoclonal antibody | — | — |
| Background | Durvalumab | Monoclonal antibody | — | — |
| Background | Pembrolizumab | Monoclonal antibody | — | — |
| Background | Retifanlimab | Monoclonal antibody | — | — |